Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) – Research analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for Intra-Cellular Therapies in a research note issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $0.50 per share for the year, down from their previous forecast of $0.55. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.59) per share.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The business had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. During the same period last year, the firm posted ($0.45) earnings per share. The company’s revenue for the quarter was up 45.7% compared to the same quarter last year.
Get Our Latest Stock Analysis on Intra-Cellular Therapies
Intra-Cellular Therapies Stock Performance
Shares of Intra-Cellular Therapies stock opened at $78.68 on Thursday. The company has a market capitalization of $8.31 billion, a P/E ratio of -67.83 and a beta of 1.00. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89. The company’s fifty day moving average is $74.33 and its two-hundred day moving average is $72.38.
Hedge Funds Weigh In On Intra-Cellular Therapies
Several hedge funds have recently bought and sold shares of the stock. Kapitalo Investimentos Ltda acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at $26,000. Headlands Technologies LLC acquired a new position in shares of Intra-Cellular Therapies in the first quarter valued at approximately $32,000. Fidelis Capital Partners LLC purchased a new position in shares of Intra-Cellular Therapies during the first quarter valued at approximately $53,000. Summit Securities Group LLC acquired a new stake in Intra-Cellular Therapies during the second quarter worth approximately $56,000. Finally, CWM LLC grew its stake in Intra-Cellular Therapies by 83.9% in the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 626 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.
Insider Activity
In related news, CEO Sharon Mates sold 53,013 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the sale, the executive vice president now owns 29,700 shares of the company’s stock, valued at $2,229,876. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sharon Mates sold 53,013 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $80,970,388.85. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 175,316 shares of company stock worth $13,037,345. Company insiders own 3.40% of the company’s stock.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Articles
- Five stocks we like better than Intra-Cellular Therapies
- What Are Dividend Contenders? Investing in Dividend Contenders
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- When to Sell a Stock for Profit or Loss
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.